Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

@article{Whitley1997GanciclovirTO,
  title={Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.},
  author={Richard J. Whitley and Gretchen A. Cloud and William Gruber and Gregory A Storch and Gail J Demmler and Richard F. Jacobs and Wayne N Dankner and Stephen A Spector and Stuart Starr and Robert F Pass and Sergio B Stagno and William J Britt and Cynthia Alford and Seng-jaw Soong and Xuelian Jamie Zhou and Lindsay Sherrill and J Mark FitzGerald and Jean Pierre Sommadossi},
  journal={The Journal of infectious diseases},
  year={1997},
  volume={175 5},
  pages={1080-6}
}
Congenital cytomegalovirus (CMV) infection occurs in approximately 1% of newborns in the United States. A phase II evaluation was done of ganciclovir for the treatment of symptomatic congenital CMV infection. Daily doses of 8 or 12 mg/kg were administered in divided doses at 12-h intervals for 6 weeks. Clinical and laboratory evaluations sought evidence of toxicity, quantitative virologic responses in urine, plasma drug concentrations, and clinical outcome. A total of 14 and 28 babies received… CONTINUE READING
62 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 62 extracted citations

Similar Papers

Loading similar papers…